Research at DOE Sites: Savannah River Site Health Effect Subcommittee (SRS).

Times and Dates: 9 a.m.–5 p.m., January 11, 1996; 9 a.m.–12 noon, January 12, 1996.

Place: Hilton—The De Soto, 15 East Liberty Street, Savannah, Georgia 31401, telephone 912/232–9000, FAX 912/232–6018.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 75 people.

Background: Under a Memorandum of Understanding (MOU) signed in December 1990 with DOE, the Department of Health and Human Services (HHS) has been given the responsibility and resources for conducting analytic epidemiologic investigations of residents of communities in the vicinity of DOE facilities, workers at DOE facilities, and other persons potentially exposed to radiation or to potential hazards from non-nuclear energy production use. HHS delegated program responsibility to CDC.

In addition, an MOU was signed in October 1990 and renewed in November 1992 between ATSDR and DOE. The MOU delineates the responsibilities and procedures for ATSDR's public health activities at DOE sites required under sections 104, 105, 107, and 120 of the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA or ''Superfund''). These activities include health consultations and public health assessments at DOE sites listed on, or proposed for, the Superfund National Priorities List and at sites that are the subject of petitions from the public; and other health-related activities such as epidemiologic studies, health surveillance, exposure and disease registries, health education, substance-specific applied research, emergency response, and preparation of toxicological profiles.

Purpose: This Subcommittee is charged with providing advice and recommendations to the Director, CDC and the Administrator, ATSDR, regarding community American Indian Tribes, and labor concerns pertaining to CDC's and ATSDR's public health activities and research at respective DOE sites. Activities shall focus on providing a forum for community, American Indian Tribal, and labor interaction and serve as a vehicle for community concern to be expressed as advice and recommendations to CDC and ATSDR.

Matters to be Discussed: This Subcommittee will listen to presentations from the Radiological Assessments Corporation, Medical University of South Carolina Cancer Registry, as well as updates on the Savannah River Site Phase II Dose Reconstruction Project findings and implications. Additional agenda items will include: the National Center for Environmental Health (NCEH) activities, the National Institute for Occupational Safety and Health and ATSDR presentations on the progress of current studies, and issues regarding the Committee selection process.

Agenda items are subject to change as priorities dictate.

Contact Persons for More Information: Paul G. Renard or Nadine Dickerson, Radiation Studies Branch, Division of Environmental Hazards and Health Effects, NCEH, CDC, 4770 Buford Highway, NE, (F–35), Atlanta, Georgia 30341–3724, telephone 770/488–7040, FAX 770/488–7044.

Dated: December 18, 1995.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 95–31152 Filed 12–21–95; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

Grassroots Regulatory Partnership Meeting; Southwest Region; Importing Commodities

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of a public meeting.

SUMMARY: The Food and Drug Administration (FDA) (Office of Regulatory Affairs, Office of the Southwest Region, and Office of External Affairs) is announcing a free public meeting to discuss ways FDA could regulate imported commodities more efficiently, improve levels of communication with industries and individuals associated with the importation of FDA-regulated commodities, and provide improved levels of consumer protection in connection with imported commodities being shipped into the United States across the United States-Mexico border. This meeting is intended to identify and evaluate opportunities for implementing the President's initiative for a partnership approach between the agency and the people affected by the work of this agency.

DATES: The public meeting will be held on Wednesday, January 31, 1996, from 9 a.m. to 12 m.

ADDRESSES: The public meeting will be held at the Concourse Clarion Hotel, Oxford Room A and B, 6789 Boeing, El Paso, TX 79926.

FOR FURTHER INFORMATION CONTACT: Barbara A. Cain, Food and Drug Administration, 300 East Eight St., rm. B123, Austin, TX 78701, 512–482–5736, or Robert G. Rast, Food and Drug Administration, 9777 Via De La Amistad, rm. 128, San Diego, CA 92173, 619–661–3273.

SUPPLEMENTARY INFORMATION: There is no registration fee for this meeting. However, due to space limitations, early registration is recommended. This meeting is intended to assist importers, brokers, and others associated with a wide variety of products being shipped through the southwest and west coast (FDA Southwest and Pacific Regions).

Dated: December 15, 1995.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 95–31195 Filed 12–21–95; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 95N–0403]

Drug Export; SURGISCREEN® 0.8 Percent, Reagent Red Blood Cells

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Ortho Diagnostic Systems, Inc., has filed an application requesting approval for the export of the human biological product SURGISCREEN® 0.8 percent, Reagent Red Blood Cells to Australia, Austria, Belgium, Canada, Denmark, The Federal Republic of Germany, Finland, France, Iceland, Ireland, Italy, Japan, Luxembourg, The Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, and The United Kingdom.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human biological products under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: Cathy E. Conn, Center for Biologics Evaluation and Research (HFM–610), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–594–2006.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of human biological products that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the Federal Register within 10 days of the filing of an application for export to facilitate public participation in its